Cargando…
A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer’s disease patients with agitation
The citalopram for Alzheimer’s disease trial evaluated citalopram for the management for agitation in Alzheimer’s disease patients. Sparse data was available from this elderly patient population. A nonlinear mixed effects population pharmacokinetic modeling approach was used to describe the pharmaco...
Autores principales: | Akil, Ayman, Bies, Robert R., Pollock, Bruce G., Avramopoulos, Dimitrios, Devanand, D. P., Mintzer, Jacobo E., Porsteinsson, Anton P., Schneider, Lon S., Weintraub, Daniel, Yesavage, Jerome, Shade, David M., Lyketsos, Constantine G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720707/ https://www.ncbi.nlm.nih.gov/pubmed/26611790 http://dx.doi.org/10.1007/s10928-015-9457-6 |
Ejemplares similares
-
Changes in QTc Interval in the Citalopram for Agitation in Alzheimer's Disease (CitAD) Randomized Trial
por: Drye, Lea T., et al.
Publicado: (2014) -
Simultaneous Quantification of Citalopram and its Main Metabolite,
Desmethylcitalopram, in Human Saliva by UHPLC
por: Dziurkowska, Ewelina, et al.
Publicado: (2018) -
Serum N-Desmethylcitalopram Concentrations are Associated with the Clinical Response to Citalopram of Patients with Major Depression
por: Ozbey, Gul, et al.
Publicado: (2018) -
Agitation in cognitive disorders: International Psychogeriatric Association
provisional consensus clinical and research definition
por: Cummings, Jeffrey, et al.
Publicado: (2015) -
POTENTIAL BENEFITS OF THC AND CBD IN THE TREATMENT OF HOSPICE-ELIGIBLE DEMENTED AND AGITATED PATIENTS
por: Mintzer, Jacobo`
Publicado: (2022)